National Centre for Pharmacoeconomics, Old Stone Building (Top Floor), Trinity Centre for Health Sciences,St. James's Hospital, Dublin 8, Ireland
Following NCPE assessment of the Applicant’s submission, cost effectiveness of ruxolitinib (Jakavi®) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement.
The NCPE considers ramucirumab not to be cost effective as either combination therapy with paclitaxel or as monotherapy, and therefore cannot recommend this drug for reimbursement at the submitted price.